دورية أكاديمية
أعرض في EDS

Direct Healthcare Costs by Level of Adherence of a Real-World Population of Statin Users in Italy.

التفاصيل البيبلوغرافية
العنوان: Direct Healthcare Costs by Level of Adherence of a Real-World Population of Statin Users in Italy.
المؤلفون: Degli Esposti L; CliCon S.r.l. Health, Economics & Outcomes Research, Bologna, Italy., Veronesi C; CliCon S.r.l. Health, Economics & Outcomes Research, Bologna, Italy., Ancona DD; Dipartimento Farmaceutico, ASL BAT, Trani, Italy., Andretta M; UOC Assistenza Farmaceutica Territoriale, Azienda ULSS 8 Berica, Vicenza, Italy., Bartolini F; Dipartimento Farmaceutico, Umbria 2, Terni, 05100, Italy., Drei A; Deloitte, Milano, Italy., Lupi A; Cardiology Unit, ASL VCO, Omegna, Italy., Palcic S; Farmaceutica Territoriale, Azienda Sanitaria Universitaria Integrata Giuliano-Isontina, Trieste, Italy., Re D; UOC Assistenza Farmaceutica Territoriale, ASL Teramo, Teramo, Italy., Rizzi FV; Dipartimento Farmaceutico, ASL BAT, Trani, Italy., Giacomini E; CliCon S.r.l. Health, Economics & Outcomes Research, Bologna, Italy., Perrone V; CliCon S.r.l. Health, Economics & Outcomes Research, Bologna, Italy.
المصدر: ClinicoEconomics and outcomes research : CEOR [Clinicoecon Outcomes Res] 2022 Mar 10; Vol. 14, pp. 139-147. Date of Electronic Publication: 2022 Mar 10 (Print Publication: 2022).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Dove Medical Press Country of Publication: New Zealand NLM ID: 101560564 Publication Model: eCollection Cited Medium: Print ISSN: 1178-6981 (Print) Linking ISSN: 11786981 NLM ISO Abbreviation: Clinicoecon Outcomes Res Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Auckland, NZ : Dove Medical Press
مستخلص: Purpose: This real-world study investigates the direct healthcare costs from the perspective of the Italian Healthcare National Service of experienced statin users according to their level of adherence to therapy and to their cardiovascular (CV) profile in Italian settings of outpatients clinical practice.
Patients and Methods: A retrospective observational analysis was performed based on administrative databases covering approximately 6 million health-assisted individuals. Adult patients with statins prescription between January 2014 and December 2016 were screened, and first prescription within this period was the index date. Follow-up lasted 1 year after index date. Only patients receiving statins prior index date (experienced statin users) were included and distributed in clusters based on their CV profile. Adherence was calculated during follow-up as proportion of days covered (PDC) and classified in low adherence (PDC<40%), partial adherence (PDC=40-79%) and adherence (PDC≥80%). Mean direct healthcare costs of drugs, hospitalizations, and outpatient services were evaluated during follow-up.
Results: A total of 436,623 experienced statin users were included and distributed as follows: 5.5% in the previous CV events, 22.6% in diabetes, 55.7% in CV treatments and 16.2% in the no comorbidity cluster. Total mean annual cost/patient decreased from low adherent to adherent patients from €4826 to €3497 in previous CV events, from €2815 to €2360 in diabetes cluster, from €2077 to €1863 for patients with CV treatments. Same trend was reported for the cost item related to hospitalizations, which was the major determinant of the total costs. In previous CV event cluster, adherence was associated to a saving of €879 on total costs.
Conclusion: The study highlighted a decrease in overall mean costs as adherence levels increase, particularly for patients with previous CV events, showing how improving adherence could be associated to cost savings and suggesting suited strategy based on CV profile should be undertaken for adherence optimization.
Competing Interests: The authors report no conflicts of interest in this work.
(© 2022 Degli Esposti et al.)
References: Patient Prefer Adherence. 2019 Aug 15;13:1375-1389. (PMID: 31496665)
J Gen Intern Med. 2022 Jan 11;:. (PMID: 35018567)
J R Soc Med. 2017 Feb;110(2):57-64. (PMID: 28084157)
Med Care. 2005 Jun;43(6):521-30. (PMID: 15908846)
Int J Cardiol. 2016 Dec 15;225:184-196. (PMID: 27728862)
Cardiovasc Drugs Ther. 2007 Aug;21(4):311-6. (PMID: 17665294)
J Chronic Dis. 1987;40(5):373-83. (PMID: 3558716)
Value Health. 2010 Jan-Feb;13(1):87-94. (PMID: 19695008)
Diabetes Ther. 2021 Sep;12(9):2371-2386. (PMID: 34292559)
Prog Cardiovasc Dis. 2021 Jan-Feb;64:111-120. (PMID: 32800791)
Int J Cardiol. 2013 Sep 30;168(2):928-33. (PMID: 23174167)
Atherosclerosis. 2011 Aug;217(2):479-85. (PMID: 21592477)
Int J Cardiol. 2017 Nov 1;246:62-67. (PMID: 28298250)
Expert Opin Pharmacother. 2009 Dec;10(18):2973-85. (PMID: 19954271)
Med Care. 2013 Aug;51(8 Suppl 3):S11-21. (PMID: 23774515)
Cardiovasc Drugs Ther. 2021 Jun 7;:. (PMID: 34097194)
Hypertens Res. 2020 Jul;43(7):705-714. (PMID: 32313192)
J Am Heart Assoc. 2017 Jun 24;6(6):. (PMID: 28647688)
Eur Heart J. 2020 Jan 1;41(1):111-188. (PMID: 31504418)
Vasc Health Risk Manag. 2018 May 24;14:91-102. (PMID: 29872306)
فهرسة مساهمة: Keywords: direct costs; lipid-lowering drugs; medication adherence; real-life
تواريخ الأحداث: Date Created: 20220318 Latest Revision: 20220319
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC8922236
DOI: 10.2147/CEOR.S345852
PMID: 35299992
قاعدة البيانات: MEDLINE
الوصف
تدمد:1178-6981
DOI:10.2147/CEOR.S345852